Valence 로고
인기
로그인

관심목록에 추가

Mesabi Trust

NYSE: MSB · 실시간 가격 · USD
23.19
+0.06 (0.26%)
종가 기준: Aug 18, 2026, 3:58 PM

Mesabi Trust (MSB) Stock Price, Analysis & Data

0.26%
매수호가n/a
시가총액304.25M
매출 (ttm)15.04M
순이익 (ttm)11.33M
베타0.33
EPS (ttm)0.86
P/E (ttm)26.97
선행 P/E-1.17
P/B (ttm)16.59
P/S (ttm)20.24
Earnings Daten/a
매도호가n/a
거래량23,288
평균 거래량 (20일)45,867
시가23.13
전일 종가23.13
일중 범위22.86 - 23.36
52주 범위21.60 - 42.38
애널리스트n/a
목표주가n/a
배당$0.89 (3.85%)
배당락일2026년 7월 30일

MSB 소개

Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. Mesabi Trust was incorporated in 1961 and is based in New York, New York....

[더 보기]
산업 Steel
섹터 Basic Materials
IPO 일자 Feb 21, 1973
직원 수 n/a
상장 거래소 NYSE
티커 MSB
웹사이트 https://mesabi-trust.com
전체 기업 정보

재무 실적

2026년 Mesabi Trust의 매출은 16.57M로, 전년 25.46M 대비 -34.91% 감소했습니다. 순이익은 13.87M로, -85.13% 감소했습니다.

재무제표

어닝 서프라이즈

Mesabi Trust가 Apr 10, 2013에 분기 실적을 발표했습니다:
  • 매출 $2.08M 예상치 하회 $0, 및 -52.23% 전년 대비 감소.
  • EPS 0.36 예상치 하회 -0.06, 및 -25.00% 전년 대비 감소.
    news image

    4개월 전 · Simply Wall St.

    Assessing Cleveland-Cliffs (CLF) Valuation After Mesabi Trust Distribution Cut Highlights Operational Uncertainty

    Mesabi Trust’s decision to cut its distribution, after receiving lower royalty payments from Cleveland-Cliffs (CLF), has drawn fresh attention to uncertainties around the miner’s Northshore iron ore o...

    news image

    4개월 전 · Simply Wall St.

    ASX April 2026 Stocks Estimated To Be Trading Below Fair Value

    The Australian stock market is experiencing a period of optimism, with the ASX 200 futures seeing a significant rise as global equities receive a boost from renewed geopolitical negotiations. Amidst t...

    news image

    4개월 전 · Simply Wall St.

    Gregory George Adds To Mesoblast Position With Multi-Market Share Purchases

    Mesoblast Limited ( ASX:MSB ) shareholders (or potential shareholders) will be happy to see that insider Gregory George...

    news image

    4개월 전 · Simply Wall St.

    Mesoblast (ASX:MSB) Is Down 11.0% After FDA Clears Registrational DMD Trial For Ryoncil - Has The Bull Case Changed?

    Mesoblast recently announced that the US FDA has granted Investigational New Drug clearance to move directly into a registrational clinical trial of Ryoncil in children with Duchenne muscular dystroph...

    news image

    4개월 전 · Simply Wall St.

    Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity?

    If you are wondering whether Mesoblast at around A$2.02 is still priced attractively or already reflecting high expectations, the valuation story matters more than ever. The share price has seen mixed...

    2 페이지 중 1